THE AUTHOR DISCUSSES ISSUES RELATED TO THE SUPPLY OF SOFT PARTS IN THE BIOPHARMA INDUSTRY.

May 1, 2013
By: Steve Jones
BioPharm International
pp. 32-33 

The biopharmaceutical industry has for a long time suffered inconsistent reliability performance of valves and diaphragms. The cost of a single batch failure can run into the millions of dollars while unplanned production stoppage and contamination investigations consume vast amounts of resources. One cause can be poor maintenance practices by the user, but as lessons are learned and practices improved, the spotlight is shifted. End users increasingly expect valve and diaphragms to deliver more consistent reliability performance through better product design, reliability testing, and improved change control. To enable this much needed transition, the time is right for the bio/pharmaceutical industry and valve and diaphragm suppliers to change the way they do business with each other.

THE ROOTS OF INCONSISTENCY 

In the past, it has been impossible to predict the life of a diaphragm until tested in the user’s full-size commercial system. Although expensive and risky, this has also meant that suppliers are often distanced from the end user’s real-world application and reliability experiences. Meanwhile, replacement parts are often supplied through distributors, further distancing suppliers from end-user’s performance issues.

Case Study, Bayer HealthCare, San Francisco

Divakar Amin, engineering manager, final product manufacturing at Bayer HealthCare, described the implications of inconsistent diaphragm valve performance to the BioPhorum Operations Group:

“I have experienced two recent incidents involving valve failure during the fill-finish process, causing leakage into a final processing operation. The cost of the lost batch each time was measured in millions of dollars. When we opened each valve up, we found that the diaphragm material had deformed because the material was not suitable for the thermal cycling of the valve.

“We need to ensure that valve manufacturers match the process application to the capabilities of their products. Bulk tanks are exposed to high temperatures during sterilization, peaking at 130 ���������C. Valve manufacturers tell us that their diaphragm material can withstand 150��C, but what they don’t tell us is how many thermal cycles their material can withstand, especially if the cycle includes low temperature processing. If the polymer is not tested against the full thermal cycle, we have no level of confidence that it’s not going to fail and leak.

“It’s very important that suppliers perform the reliability testing in the lab and tell us how many thermal cycles the diaphragms will sustain. Without this information I’m left having to change-out my diaphragms every three months because I simply cannot risk losing another batch.”

INCONSISTENT CHANGE CONTROL 

Barak Barnoon, director of process engineering and analytics at Pfizer, raised another example of inconsistent diaphragm valve performance in real-world applications to the BioPhorum Operations Group:

“What is missing currently, is control on their part of their suppliers and their diaphragm raw materials. We have seen impaired performance due both to changes in their sourcing and also in the manufacturing processes of their diaphragm suppliers. There’s a big opportunity to increase the level of control and good manufacturing practices.”

Divakar cites a further example of inadequate change control:

“If very small changes are made to the diaphragm material, then they can have a big impact on performance. We have experienced a situation where an autoclave valve was replaced with an ‘identical’ product. Subsequently, the heat-up time of the autoclave went out of its validated range. After extensive investigations we discovered a very minor, undisclosed change to the valve that impacted the process.”

THE INDUSTRY IS MOVING IN THE RIGHT DIRECTION 

Until now, biopharma companies have responded to inconsistent valve and diaphragm reliability performance by adopting a strategy of excessive preventative maintenance, but this strategy carries unacceptable cost and has limited effectiveness.

Today, the situation is changing, and the winning suppliers will be those who are able to demonstrate and guarantee the reliable performance of their products. Customers increasingly want to see products rigorously rig-tested using test cycles that mimic the full-scale plant, especially for valves and diaphragms installed onto crucial installations.

Barnoon sums it up:

“It would be good to have more testing that is indicative of performance. There’s testing right now that examines critical characteristics of a diaphragm, there’s testing that gives you chemical compatibility, but some of the manufacturers are starting to look at testing that is more predictive of performance over multiple cycles. It would be good if this were something the whole industry could move toward.”

To this end, the end-user community has rallied together to establish a common test cycle to be used by suppliers for reliability testing. These requirements are now being absorbed into technical standards through partnerships with organizations such as the American Society of Mechanical Engineering, BioProcessing Equipment (ASME BPE). This is simply following the lead of other industries, such as nuclear, aerospace, and automotive, which have gone through similar transitions in the past.

It should be recognized that the necessary investment in time, skills, energy, and utility systems to carry out this testing can be considerable, even if representative accelerated tests can be developed. The question is, who is going to pay?

The answer is that the costs of early and uncontrolled failure on full-scale plants are already being paid by the end user. These costs are so huge that end-users are increasingly prepared to do business only with those suppliers that are able to demonstrate reliability and can show the test data to prove it. In short, testing will become a cost of doing business in the biopharmaceutical industry. This is not to say that end-users are unwilling to pay; it’s only reasonable to expect to pay a premium inline with an increase in performance.

Bayer’s Amin states:

“Currently, we are paying much more in terms of failure that affects our process rather than paying more for a reliable diaphragm backed up with solid test data. Not only Bayer, but every manufacturer in the industry because they also know the cost of lost batches. The industry is more than willing to pay for reliability. When fully cycle tested diaphragms are available in the marketplace, I’ll be at the front of the queue.”

Trends in Soft Parts

Users, then, are willing to pay a premium for products that are proven to be more reliable. Users expect to pay more for product longevity, reliability, and test data. They will increasingly be expecting to see these features and costs wrapped into their commercial agreements with suppliers.

Change, of course, is never easy, and there will be growing pains for both suppliers and customers as the industry moves through this much needed transition. As always, with industry-wide change, there will be those organizations that recognize the opportunity quickly and become the early movers to gain market share. There will then be the fast followers that realize that they risk losing market share, which will quickly spur them into action. There are then the followers who will change only when industry standards and expectations have changed. Lastly, there will be those that will not change: they will either have such a superior product that they can ignore the new service features offered by their competitors or they have to exit the market.

Steve Jones is a director at the BioPhorum Operations Group,steve@biophorum.com

Contact address

BioPhorum
The Gridiron Building
One Pancras Square
London
N1C 4AG

Newsletter subscribe

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.



© 2019 Biophorum Operations Group · All Rights Reserved

Registered Address: 5 Westbrook Court · 2 Sharrow Vale Road · Sheffield · S11 8YZ

Company Number 06794795 · VAT Number GB298617544

Driving progress in Cell & Gene Therapy

Now with 19 member companies and 183 subject matter experts, the BioPhorum Cell & Gene Therapy (C>) Phorum has made great strides since its formation[...]

Read More
Join BioPhorum at BioProcess International events

We have partnered with BioProcess International for more than five years. In that time, their conferences have provided platforms to socialize the collaboration’s key new[...]

Read More
Cell and Gene Therapy Phorum accelerates progress

The BioPhorum Cell & Gene Therapy Phorum has made significant progress since its creation in 2018 – from building networks and sharing knowledge to endorsing[...]

Read More
The BioPhorum and USP collaborative journey to new standards

BioPhorum and United States Pharmacopeia (USP) share a common direction – to accelerate biopharma innovation, quality and progress through collaboration.

Read More
Perfecting balanced scorecards for CDMOs

Established in March 2017, the Development Group’s Development Outsourcing effort aims to share and build guidance that will help companies make the best decisions and[...]

Read More
Formulation team drive for more value

Since its start in 2013, the Formulation Point Share has been busy. Its latest article, An inter-company perspective on biopharmaceutical drug product robustness studies, was[...]

Read More
Join BioPhorum at BioProcess International events

We have partnered with BioProcess International for more than five years. In that time, their conferences have provided platforms to socialize the collaboration’s key new[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
Why leaders should go to where work is performed to learn about success, failure and risk
Read More
Hi-tech ambitions for Fill Finish

The Fill Finish Phorum has recently embarked on a series of exciting and ambitious initiatives, exploring new technologies and processes to enhance the efficiency and[...]

Read More
Companies poised to follow ARMM recommendations

The Advanced and Rapid Microbial Methods (ARMM) team set out a clear case for modernizing Environmental Monitoring (EM) in grade A settings: in summary bio-fluorescent[...]

Read More
How to achieve the ‘Goldilocks’ amount of environmental monitoring

Regulators require a risk-based approach to environmental monitoring (EM)… but they give no clear definition of what “risk-based” actually means. The aim of the Environmental[...]

Read More
The ‘how to’ guide to implementing Agile in GxP

The publication of the Guidance on the use of Agile in a GxP Environment document in 2017 was well received.It described how the use of[...]

Read More
How smart is your maintenance?

Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
Join BioPhorum at BioProcess International events

We have partnered with BioProcess International for more than five years. In that time, their conferences have provided platforms to socialize the collaboration’s key new[...]

Read More
Supply chain, forecasting and demand planning solutions gain momentum

The relationship between suppliers and manufacturers is one of the most crucial in biopharmaceutical manufacturing. This is especially the case when forecasting and supply planning.[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
Changing mindsets with a modular approach

Historically, manufacturers have used a ‘waterfall’ approach when designing and building their production facilities, sequentially resolving and specifying all aspects up front and in detail[...]

Read More
Join BioPhorum at BioProcess International events

We have partnered with BioProcess International for more than five years. In that time, their conferences have provided platforms to socialize the collaboration’s key new[...]

Read More
How do you bring technology roadmapping to life?

You use it to make change happen and that is exactly what the Phorum’s leaders did after the first edition of the Biomanufacturing Technology Roadmaps[...]

Read More
Slicing years off change implementation

As the first regulatory authority in Latin America to gain full membership of the International Council for Harmonization (ICH), the Brazilian Health Regulatory Agency (Anvisa)[...]

Read More
BioPhorum Regulatory Interaction: helping to open doors

To implement any change in the biopharmaceutical manufacturing industry it is important to engage with and collaborate with the regulators. Set up two years ago,[...]

Read More

IaaS Cloud webinar recording play back
Read More
New BPIT guidance to align cloud services to regulatory requirements
Read More
Data Integrity and Agile Webinars to support industry response to regulators
Read More
How to validate informatics in CPV programs

The BioPhorum Continued Process Verification (CPV) and Informatics team has published a paper to support a risk-based approach for the validation of informatics systems for[...]

Read More
Continued Process Verification delivering real saving in time and money

More than 50 per cent of biopharma products on the market now have Continued Process Verification (CPV) plans in place.  Thanks to the CPV white[...]

Read More
A roadmap for the implementation of continued process verification

This article provides a roadmap draws on the content of the CPV case study to provide a step-by-step guide in a more accessible form.

Read More
How smart is your maintenance?

Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

Read More
Digital plant maturity model webinar replay
Read More
Digital Plant Maturity Model workstream to host webinar
Read More
New guidance available on Forecasting and Demand Planning to streamline supply chain performance
Read More
Host cell proteins poster

This poster presented at the BEBPA Conference, San Francisco builds and consolidates the information currently available in the industry for assessing process risk from Host[...]

Read More
Host cell protein risk assessment, an industry approach

Host cell protein (HCP) constitutes a significant class of process-related impurities in biological drugs.

Read More
BEBPA risk assessment workshop
Read More
New toolkit to accelerate single-use design and specification

The single-use user requirements toolkit is now live and available for free download on the BioPhorum website  The toolkit streamlines the design and specification process[...]

Read More